Long-term effect on body composition and metabolic parameters after treatment with recombinant human growth hormone (r-hGH) in HIV-1 infected patients with lipodystrophy.

Plain-language guide to PMID 17852925 (2008): pilot randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 20 subjects.

Key Facts

PMID: 17852925
Journal: Scandinavian journal of infectious diseases
Year: 2008
Study type: Randomized Controlled Trial
Authors: Bickel M et al. (10 authors)
DOI: 10.1080/00365540701487955

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

T1 weighted MRI flash sequences were performed of the face, abdomen and at mid-thigh level (MTF) at baseline, week 12, week 24 and at follow-up.

Of 20 subjects who completed the 24-week study, follow-up is available for 16 patients (15 male, mean age 44.8 y, mean duration of HIV infection 13.5 y).

Who Took Part

According to the abstract, 20 subjects were involved.

PubMed indexes the participants as teenagers, adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized and pilot study.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

It is described as a pilot, a small early test of whether a larger Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study would be practical.

What Was Measured

T1 weighted MRI flash sequences were performed of the face, abdomen and at mid-thigh level (MTF) at baseline, week 12, week 24 and at follow-up.

PubMed files the paper under topics including Antiretroviral Therapy, Highly Active, Body Fat Distribution, HIV Infections, HIV-1, HIV-Associated Lipodystrophy Syndrome, Human Growth Hormone and Intra-Abdominal Fat.

What This Means in Plain Language

The paper is a randomized and pilot study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 20 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2008 (Scandinavian journal of infectious diseases), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.

Our Notes on the Compound

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.